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httpcense.Abstract Background: Biological markers such as procalcitonin, may be helpful for the diagnosis
of HAP. Procalcitonin has greater diagnostic accuracy than most commonly used clinical parame-
ters and other biomarkers of infection, such as C-reactive protein and ESR. The aim of the study
was to assess the etiological and prognostic values of procalcitonin in adult patients with hospital
acquired pneumonia (HAP).
Methods: 15 Patients with a strong suspicion of hospital acquired pneumonia. The diagnosis of
HAP depends on the clinical criteria of pulmonary infection and presence of radiological ﬁndings.
Complete blood picture, sputum culture and sensitivity, ESR, CRP and PCT were obtained at
admission and repeated after 2 weeks. PCT was determined with Elecsys BRAHMS PCT in serum
of studied patients.
Results: Serum PCT above 0.5 lg/L was considered highly positive for diagnosis of HAP. It was
signiﬁcantly higher at admission (2.72 ± 1.72 lg/L) than after two weeks (1.0 ± 1.91 lg/L). Therein levels; ESR, erythrocyte
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202 A.E. Abu Elkhashab et al.was a statistical signiﬁcant decrease in serum levels of procalcitonin (P= 0.002) in response to anti-
biotic therapy. Also the PCT was signiﬁcantly higher in patients with bad outcome (2.11–6.0 lg/L)
than patients with good outcome (1.76 ± 0.69 lg/L). Procalcitonin was signiﬁcantly higher among
patients with pseudomonas (5.53 ± 0.50 lg/L) and acinetobacter (2.67 ± 0.49 lg/L) and lesser
among patients with Escherichia coli (1.38 ± 0.06 lg/L) and MRSA (1.09 ± 0.13 lg/L).
Conclusion: Procalcitonin was a good etiological and prognostic marker in hospital acquired
pneumonia. PCT is the most speciﬁc biomarker and has a number of advantages over previous
markers.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. Open access under CC BY-NC-ND license.Introduction
Hospital-acquired pneumonia (HAP) or nosocomial pneumo-
nia (NP) is deﬁned as pneumonia that occurs 48 h or more
after hospital admission while, ventilator associated pneumo-
nia (VAP) refers to pneumonia that arises more than 48–72 h
after endotracheal intubation. HAP accounts up to 25% of
all ICU infections and for more than 50% of antibiotic pre-
scribed. However the incidence of VAP varied between 9%
and 27% of all intubated patients in different studies.
Time of onset of pneumonia is an important epidemiologic
variable and risk factor for speciﬁc pathogens and outcomes in
patients with HAP and VAP. Early- onset HAP and VAP, de-
ﬁned as occurring within the ﬁrst 4 days of hospitalization,
usually carry a better prognosis, and are more likely to be
caused by antibiotic sensitive bacteria. Late-onset HAP and
VAP (5 days or more) are more likely to be caused by multi-
drug resistant (MDR) pathogens, and are associated with in-
creased patient mortality and morbidity. It is a common
condition, difﬁcult to diagnose accurately, and expensive to
treat. Its development prolongs patient stay in the intensive
care unit (ICU), and is associated with signiﬁcant morbidity
and mortality.
The approach to the patient with pneumonia begins with
the clinical examination, followed by radiographic and micro-
biologic testing. Blood tests including a complete blood count,
serum electrolytes, C-reactive protein, procalcitonin, and pos-
sibly liver function tests are recommended.
Procalcitonin, the precursor molecule of calcitonin, is a
116-amino acid and is produced by parafollicular cells of the
thyroid and by the neuroendocrine cells of the lung and intes-
tine. It is secreted from medullary cells.
Serum levels of procalcitonin are very low in healthy indi-
viduals. Despite little being known about the biologic proper-
ties of procalcitonin and its origin, procalcitonin levels rise
during bacterial infections but not during viral infections or
inﬂammatory reactions of noninfectious origin.
Measurement of procalcitonin can be used as a marker of
severe sepsis and generally grades well with the degree of sepsis
[1]. Although levels of procalcitonin in the blood are very low
PCT has the greatest sensitivity (85%) and speciﬁcity (91%)
for differentiating patients with SIRS (Systemic Inﬂammatory
Response Syndrome) from those with sepsis, when compared
with IL-2, IL-6, IL-8, CRP and TNF-alpha [2]. Evidence is
emerging that procalcitonin levels can reduce unnecessary anti-biotic prescribing to people with lower respiratory tract infec-
tions [3]. Procalcitonin levels may be useful to distinguish
bacterial infections from nonbacterial infection [4].Materials and methods
The study included 15 patients with hospital acquired pneumo-
nia. These patients were admitted to the chest department of
Alexandria main university hospital. Written informed consent
was obtained from all patients or one of their relatives to par-
ticipate in this study. Adult patients with pneumonia develop-
ing 48 h or more after admission with Symptoms of acute
infection (fever, leucocytosis, tachypnea, tachycardia) and
presence of recent inﬁltrates on CXR. Exclusion criteria were
other causes of increased procalcitonin level such as Septic
shock, Neuroendocrine tumors, Non infectious systemic
inﬂammation (pulmonary aspiration, inhalation injury), Trau-
ma, burns and surgery. All subjects were subjected to thorough
history taking, full clinical examination, complete blood pic-
ture, Alanine minotransaminase, Aspartate Aminotransamin-
ase, urea, creatinine, ESR, and CRP. Serum procalcitonin
levels [5–7] were estimated with Elecsys BRAHMS PCT ref.
05056888 200 in serum of studied patients at the time of admis-
sion and follow up after 2 weeks of therapy.
Test principle
Sandwich principle. Total duration of assay: 18 minutes. 1st
incubation: Antigen in the sample (30 lL), a biotinylated
monoclonal PCT-speciﬁc antibody, and a monoclonal PCT-
speciﬁc antibody labeled with a ruthenium complex react to
form a sandwich complex. 2nd incubation: After addition of
streptavidin- coated microparticles, the complex becomes
bound to the solid phase via interaction of biotin and strepta-
vidin. The reaction mixture is aspirated into the measuring cell
where the micro particles are magnetically captured onto the
surface of the electrode. Unbound substances are removed
with procell. Application of a voltage to the electrode then in-
duces chemiluminescent emission which is measured by a pho-
tomultiplier. Results are determined via a calibration curve
which is instrument-speciﬁcally generated by 2-point calibra-
tion and a master curve provided via the reagent barcode.
The analyzer automatically calculates the analyte concentra-
tion of each sample in ng/ml.
Table 1 Comparison of procalcitonin levels among different causative organism.
p: p value for Kruskal Wallis test.
p1: p value for Mann Whitney test between pseudomonas with each other group.
p2: p value for Mann Whitney test between Acinetobacter with each other group.
p3: p value for Mann Whitney test between Klebsiella with E. coli and MRSA.
p4: p value for Mann Whitney test between E. coli and MRSA.
WXRp: p value for Wilcoxon signed ranks test between admission and after 2 weeks in each organism.
*Statistically signiﬁcant at p 6 0.05.
Table 2 Correlation between CRP, procalcitonin and ESR on admission.
rs: Spearman coefﬁcient.
*Statistically signiﬁcant at p 6 0.05.
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Data were analyzed using SPSS software package version 18.0
(SPSS, Chicago, IL, USA). Quantitative data were expressed
using range, mean, standard deviation and median while Qual-
itative data were expressed in frequency and percent. Qualita-tive data were analyzed using Chi-square test also exact tests
such as Fisher exact were applied to compare different groups.
Quantitative data were analyzed using Student’s t-test to com-
pare between two groups.Not normally distributed quantitative
data were analyzed usingMannWhitney test for comparing two
groups. P value was assumed to be signiﬁcant at 0.05.
Table 3 Correlation between CRP, procalcitonin and ESR after 2 weeks of therapy.
rs: Spearman coefﬁcient.
*Statistically signiﬁcant at p 6 0.05.
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Figure 1 Correlation between ESR 1st hour and CRP on
admission.
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Figure 2 Correlation between ESR (2nd hour) and CRP on
admission.
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Figure 3 Correlation between ESR 1st and CRP after 2 weeks of
therapy.
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Figure 4 Correlation between ESR 2nd and CRP after 2 weeks
of therapy.
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This study included 15 patients with, clinical, radiological and
bacteriological evidences of HAP. These patients were admit-
ted to the chest department of Alexandria main university hos-
pital during the period between 2/5/2012 and 30/7/2012.Table 1 compared procalcitonin level in relation to the dif-
ferent causative organisms. Procalcitonin level was higher in
pseudomonas and acinetobacter and was lesser in Escherichia
coli and MRSA.
Data presented in Tables 2 and 3 and Figs. 1–4 showed the
relationship between procalcitonin, CRP, and ESR on admis-
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Figure 5 Comparison between different clinical outcomes of the
studied patients regarding procalcitonin levels on admission and
after 2 weeks of speciﬁc antibiotic therapy.
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positive correlation with ESR during the 1st and 2nd hour
both on admission and after 2 week treatment. Whereas, pro-
calcitonin levels showed an insigniﬁcant correlation with CRP
and ESR (1st, 2nd hours) both on admission and after 2 week
treatment.
Table 3 and Figure 5 compared between different clinical
outcomes of the studied patients regarding procalcitonin levels
at admission and after 2 weeks of therapy. There was a statis-
tically signiﬁcant difference between total and partial clinical
improvement (p= 0.011) on admission. There was a statisti-
cally signiﬁcant difference between total and partial clinical
improvement (p= 0.005) after 2 weeks. There was a signiﬁ-
cant improvement in procalcitonin levels after 2 week treat-
ment in patients with total improvement, while those with
partial improvement showed an insigniﬁcant change. Compar-Table 4 Comparison between different clinical outcomes of the stud
2 weeks of speciﬁc antibiotic therapy.
p: p value for Mann Whitney test between totally improved and partially
p1: p value for Mann Whitney test between died with totally improved a
p2: p value for Mann Whitney test between totally improved and partiall
WXRp: p value for Wilcoxon signed ranks test between admission and aft
*Statistically signiﬁcant at p 6 0.05.ing % change in procacitonin levels after 2 week treatment
there was a signiﬁcant higher decrease among patients with to-
tal clinical improvement (WSRp= 0.005).Discussion
Table 4 HAP is the second most common nosocomial infection
in the United States. There are 300,000 cases of HAP annually,
and it carries an associated mortality rate of 30–70% [8]. It is
difﬁcult to determine the fraction of patients with HAP whose
mortality is directly attributable to their pneumonia (the
attributable mortality), but this rate is estimated to be between
27% and 50% [8,9]. This means that of the patients who devel-
op HAP, it will be the proximate cause of death in 25–50% of
them, and the remaining 50–75% will develop HAP but die
from some other cause. HAP lengthens the hospital stay by
7–9 days and is associated with a higher cost of medical care.
A meta-analysis about the diagnostic value of procalcitonin
in bactremia reported a sensitivity of 76% and speciﬁcity of
70% [10]. Cluster randomized trial found that the procalcito-
nin level can help guide antibiotic therapy. In this trial, ‘‘on
the basis of serum procalcitonin concentrations, use of antibi-
otics was more or less discouraged (<0.1 lg/L or <0.25 lg/L)
or encouraged (P0.5 lg/L or P0.25 lg/L), respectively [11].
Our results showed that serum procalcitonin concentrations
were higher in patients with unfavorable outcomes (died) than
in patients with favorable outcomes (survived) [12,13]. The
current study was carried out to assess the etiological and
prognostic values of procalcitonin in adult patients with hospi-
tal acquired pneumonia (HAP).
Lee et al. (2010) reported that Serum PCT level was a better
marker than CRP level or ESR for the diagnosis of lobar pneu-
monia and distinguish severe bacterial infections from viral
infections [14].
Elizabeth et al. (2011) reported that comparison of procalc-
itonin with other biomarkers, earlier spike (after 4 h ofied patients regarding procalcitonin levels at admission and after
improved.
nd partially improved.
y improved.
er 2week.
206 A.E. Abu Elkhashab et al.infection) in levels and more rapid decrease with clinical
improvement, not signiﬁcantly affected by steroids or non-ste-
roidal anti-inﬂammatory drugs, not dependent on WBCs (PCT
levels elevated in study of neutropenic patients with proven
bacterial infection) [15,16].
Robert et al. (2011) demonstrated that PCT is associated
with the severity of illness in patients with severe pneumonia
and appears to be a prognostic marker of morbidity and mor-
tality comparable to the APACHE II score. PCT-val-
ues < 0.1 ng/ml in HAP were associated with a low risk of
death independent of the clinical risk assessment [17,18].
PCT was also capable of identifying an unfavorable outcome
in HAP patients staying at the ICU [19].
Luyt and colleagues reported that PCT levels decreased
during the clinical course of VAP but were signiﬁcantly higher
from Day 1 to Day 7 in patients with unfavorable outcomes
[20].
Supporting our data Bloos et al. (2011) showed that in com-
parison between different causative organisms procalcitonin is
higher in pseudomonas than other organisms [21].
Simon et al. reported that decreasing levels of PCT is a ﬁnd-
ing that shows improvement of infectious clinic while increas-
ing levels of PCT should be considered as a poor prognostic
sign [22].
In conclusion from this study
Procalcitonin Kinetic was a good etiological and prognostic
marker in hospital acquired pneumonia. PCT is the most spe-
ciﬁc biomarker and has a number of advantages over previous
markers. PCT is a better marker than CRP, ESR for the prog-
nosis of HAP. Differences in the PCT values can be used for
the prediction of prognosis. Decreasing levels of PCT is a ﬁnd-
ing that indicates improvement of infection. Increasing levels
of PCT should be considered as a poor prognostic sign. PCT
may help clinicians to predict classic bacteria and subsequently
to select empiric antimicrobial therapy.
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